Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene hunt for rare cancers aims to unlock new treatments

NCT ID NCT02688517

Knowledge-focused Sponsor: Rutgers, The State University of New Jersey Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This research study is looking at the genetic makeup of tumors from 1,100 people with rare or hard-to-treat cancers. By analyzing blood and tissue samples, scientists hope to find specific gene changes that could lead to better diagnosis and more effective treatments. The goal is to understand which genetic mutations are most common in these cancers and how they might be targeted with existing or new therapies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,100 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Feb 2013

Expected to finish

May 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Persons with Cancer

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Karnofsky/Lansky performance score \>= 30 * A signed written informed consent * Evaluation in surgical/medical/radiation oncology/radiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and/or poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment * Paraffin blocks of the patient's tumor tissue are available and accessible for analysis Exclusion Criteria: * Karnofsky/Lansky performance score \< 30 * Life expectancy \< 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malignant neoplasm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malignant neoplasm

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Bayshore Community Hospital

    COMPLETED

    Holmdel, New Jersey, 07733, United States

  • Jersey Shore Medical Center

    COMPLETED

    Neptune City, New Jersey, 07753, United States

  • Morristown Medical Center

    COMPLETED

    Morristown, New Jersey, 07960, United States

  • Ocean Medical Center

    COMPLETED

    Brick, New Jersey, 08724, United States

  • Overlook Hospital

    COMPLETED

    Summit, New Jersey, 07902, United States

  • RWJBarnabas Health - Jersey City Medical Center, Jersey City

    RECRUITING

    Jersey City, New Jersey, 07302, United States

  • Riverview Medical Center

    ACTIVE_NOT_RECRUITING

    Red Bank, New Jersey, 07701, United States

  • Riverview Medical Center/Booker Cancer Center

    COMPLETED

    Red Bank, New Jersey, 07701, United States

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08903, United States

  • Southern Ocean County Medical Center

    COMPLETED

    Manahawkin, New Jersey, 08050, United States

  • University of Wisconsin Hospital and Clinics

    WITHDRAWN

    Madison, Wisconsin, 53792, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.